Resum
Background: Currently, there are no biomarkers to predict respiratory worsening
in patients with Coronavirus infectious disease, 2019 (COVID- 19) pneumonia.
Objectives: We aimed to determine the prognostic value of Krebs von de Lungen-6 circulating serum levels (sKL-6) predicting COVID- 19 evolving trends.
Methods: We prospectively analyzed the clinical and laboratory characteristics of 375 COVID- 19 patients with mild lung disease on admission. sKL-6 was
obtained in all patients at baseline and compared among patients with respiratory worsening.
Results: 45.1% of patients developed respiratory worsening during hospitalization. Baseline sKL-6 levels were higher in patients who had respiratory worsening
(median [IQR] 303 [209-449] vs. 285.5 [15.8-5724], P=0.068). The best sKL-6
cut-off point was 408U/mL (area under the curve 0.55; 33% sensitivity, 79%
specificity). Independent predictors of respiratory worsening were sKL-6 serum
levels, age >51 years, time hospitalized, and dyspnea on admission. Patients
with baseline sKL-6 ≥ 408U/mL had a 39% higher risk of developing respiratory
aggravation seven days after admission. In patients with serial determinations,
sKL-6 was also higher in those who subsequently worsened (median [IQR] 330
[219-460] vs 290.5 [193-396]; p<0.02).
Conclusion: sKL-6 has a low sensibility to predict respiratory worsening in
patients with mild COVID-19 pneumonia. Baseline sKL-6 ≥ 408U/mL is associated to a higher risk of respiratory worsening. sKL-6 levels are not useful as a
screening tool to stratify patients on admission but further research is needed to
investigate if serial determinations of sKL-6 may be of prognostic use
in patients with Coronavirus infectious disease, 2019 (COVID- 19) pneumonia.
Objectives: We aimed to determine the prognostic value of Krebs von de Lungen-6 circulating serum levels (sKL-6) predicting COVID- 19 evolving trends.
Methods: We prospectively analyzed the clinical and laboratory characteristics of 375 COVID- 19 patients with mild lung disease on admission. sKL-6 was
obtained in all patients at baseline and compared among patients with respiratory worsening.
Results: 45.1% of patients developed respiratory worsening during hospitalization. Baseline sKL-6 levels were higher in patients who had respiratory worsening
(median [IQR] 303 [209-449] vs. 285.5 [15.8-5724], P=0.068). The best sKL-6
cut-off point was 408U/mL (area under the curve 0.55; 33% sensitivity, 79%
specificity). Independent predictors of respiratory worsening were sKL-6 serum
levels, age >51 years, time hospitalized, and dyspnea on admission. Patients
with baseline sKL-6 ≥ 408U/mL had a 39% higher risk of developing respiratory
aggravation seven days after admission. In patients with serial determinations,
sKL-6 was also higher in those who subsequently worsened (median [IQR] 330
[219-460] vs 290.5 [193-396]; p<0.02).
Conclusion: sKL-6 has a low sensibility to predict respiratory worsening in
patients with mild COVID-19 pneumonia. Baseline sKL-6 ≥ 408U/mL is associated to a higher risk of respiratory worsening. sKL-6 levels are not useful as a
screening tool to stratify patients on admission but further research is needed to
investigate if serial determinations of sKL-6 may be of prognostic use
| Idioma original | Anglès |
|---|---|
| Pàgines (de-a) | 1365-1365 |
| Nombre de pàgines | 1 |
| Revista | Annals of the Rheumatic Diseases |
| Volum | 80 |
| Número | Supl. 1 |
| DOIs | |
| Estat de la publicació | Publicada - 2021 |
SDG de les Nacions Unides
Aquest resultat contribueix als següents objectius de desenvolupament sostenible.
